KalVista Pharmaceuticals (KALV) Change in Accured Expenses (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Change in Accured Expenses of -$8.2 million in Q3 2025, down 201.04% quarter-over-quarter from $8.1 million in Q2 2025, and down 361.66% year-over-year from $3.1 million in Q3 2024.
KalVista Pharmaceuticals' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at -$8.2 million for Q3 2025.
- In Q3 2025, Change in Accured Expenses fell 361.66% year-over-year to -$8.2 million; the TTM figure through Jul 2025 stood at $3.2 million (up 18.86% YoY), while the FY2025 annual figure was $14.4 million, up 349.64% from the prior year.
- Change in Accured Expenses came in at -$8.2 million for Q3 2025 at KalVista Pharmaceuticals, down from $8.1 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $8.1 million in Q2 2025 to a low of -$8.2 million in Q3 2025.
- A 5-year average of $468777.8 and a median of $368000.0 in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses sank 1154.11% in 2024 and jumped 433.26% in 2025, its largest moves.
- KalVista Pharmaceuticals' Change in Accured Expenses stood at $217000.0 in 2021, then soared by 374.19% to $1.0 million in 2022, then soared by 290.09% to $4.0 million in 2023, then climbed by 25.49% to $5.0 million in 2024, then tumbled by 262.78% to -$8.2 million in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$8.2 million, $8.1 million, and $5.0 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -8.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -8.20 Mn |
| Jul 31, 2025 | -8.20 Mn |
| Apr 30, 2025 | 8.12 Mn |
| Apr 30, 2025 | 8.12 Mn |
| Oct 31, 2024 | 5.04 Mn |
| Oct 31, 2024 | 5.04 Mn |
| Jul 31, 2024 | -1.78 Mn |
| Jul 31, 2024 | -1.78 Mn |
| Apr 30, 2024 | -2.44 Mn |
| Apr 30, 2024 | -2.44 Mn |
| Jan 31, 2024 | 2.87 Mn |
| Jan 31, 2024 | 2.87 Mn |
| Oct 31, 2023 | 4.01 Mn |
| Oct 31, 2023 | 4.01 Mn |
| Jul 31, 2023 | -1.24 Mn |
| Jul 31, 2023 | -1.24 Mn |
| Apr 30, 2023 | 231,000.00 |
| Apr 30, 2023 | 231,000.00 |
| Jan 31, 2023 | 1.72 Mn |
| Jan 31, 2023 | 1.72 Mn |
| Oct 31, 2022 | 1.03 Mn |
| Oct 31, 2022 | 1.03 Mn |
| Jul 31, 2022 | -1.04 Mn |
| Jul 31, 2022 | -1.04 Mn |
| Apr 30, 2022 | 751,000.00 |
| Apr 30, 2022 | 751,000.00 |
| Jan 31, 2022 | 505,000.00 |
| Jan 31, 2022 | 505,000.00 |
| Oct 31, 2021 | 217,000.00 |
| Oct 31, 2021 | 217,000.00 |
| Jul 31, 2021 | -1.00 Mn |
| Jul 31, 2021 | -1.00 Mn |
| Apr 30, 2021 | 1.52 Mn |
| Apr 30, 2021 | 1.52 Mn |
| Jan 31, 2021 | -1.87 Mn |
| Jan 31, 2021 | -1.87 Mn |
| Oct 31, 2020 | 797,000.00 |
| Oct 31, 2020 | 797,000.00 |
| Jul 31, 2020 | 538,000.00 |
| Jul 31, 2020 | 538,000.00 |
| Apr 30, 2020 | 718,000.00 |
| Apr 30, 2020 | 718,000.00 |
| Jan 31, 2020 | -202,000.00 |
| Jan 31, 2020 | -202,000.00 |
| Oct 31, 2019 | 553,000.00 |
| Oct 31, 2019 | 553,000.00 |
| Jul 31, 2019 | -1.12 Mn |
| Jul 31, 2019 | -1.12 Mn |
| Apr 30, 2019 | 2.25 Mn |
| Apr 30, 2019 | 2.25 Mn |
| Jan 31, 2019 | 351,000.00 |
| Jan 31, 2019 | 351,000.00 |
| Oct 31, 2018 | -91,000.00 |
| Oct 31, 2018 | -91,000.00 |
| Jul 31, 2018 | 157,000.00 |
| Jul 31, 2018 | 157,000.00 |
| Apr 30, 2018 | 800,000.00 |
| Apr 30, 2018 | 800,000.00 |
| Jan 31, 2018 | -33,000.00 |
| Jan 31, 2018 | -33,000.00 |
| Oct 31, 2017 | 550,000.00 |
| Oct 31, 2017 | 550,000.00 |
| Jul 31, 2017 | -185,000.00 |
| Jul 31, 2017 | -185,000.00 |
| Apr 30, 2017 | -371,000.00 |
| Apr 30, 2017 | -371,000.00 |
| Jan 31, 2017 | -438,000.00 |
| Jan 31, 2017 | -438,000.00 |
| Oct 31, 2016 | -376,000.00 |
| Oct 31, 2016 | -376,000.00 |
| Jul 31, 2016 | -746,000.00 |
| Jul 31, 2016 | -746,000.00 |
| Mar 31, 2016 | -246,000.00 |
| Mar 31, 2016 | -246,000.00 |
| Dec 31, 2015 | 37,000.00 |
| Dec 31, 2015 | 37,000.00 |
| Sep 30, 2015 | -394,000.00 |
| Sep 30, 2015 | -394,000.00 |
| Jun 30, 2015 | -87,000.00 |
| Jun 30, 2015 | -87,000.00 |
| Mar 31, 2015 | 146,000.00 |
| Mar 31, 2015 | 146,000.00 |
| Sep 30, 2014 | 640,000.00 |
| Sep 30, 2014 | 640,000.00 |
| Jun 30, 2014 | 217,000.00 |
| Jun 30, 2014 | 217,000.00 |
| Mar 31, 2014 | 118,000.00 |
| Mar 31, 2014 | 118,000.00 |